MTIC

• Description :

  MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity [1][2][3][4].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Drug Metabolite

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/mtic.html

• Purity :

  99.51

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=C(/N=N/NC)N=CN1)N

• Molecular Formula :

  C5H8N6O

• Molecular Weight :

  168.16

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Nagasawa HT, et al. The mechanism of alkylation of DNA by 5- (3-methyl-1-triazeno) imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388) . Non-involvement of diazomethane. Chem Biol Interact. 1974 Jun;8 (6) :403-13.|[3]Tsang LL, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl- (triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27 (5) :342-6.|[4]Beal DD, et al. Carcinogenicity of the antineoplastic agent, 5- (3,3-dimethyl-1-triazeno) -imidazole-4-carboxamide, and its metabolites in rats. J Natl Cancer Inst. 1975 Apr;54 (4) :951-7.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [3413-72-7]